Capital Fund Management S.A. decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 66.1% during the second quarter, according to its most recent filing with the SEC. The firm owned 169,434 shares of the company’s stock after selling 329,998 shares during the period. Capital Fund Management S.A.’s holdings in Zoetis were worth $10,569,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of ZTS. BlackRock Inc. increased its position in Zoetis by 2,471.1% during the 1st quarter. BlackRock Inc. now owns 36,082,470 shares of the company’s stock valued at $1,925,722,000 after purchasing an additional 34,679,064 shares during the period. Morgan Stanley increased its position in Zoetis by 182.5% during the 1st quarter. Morgan Stanley now owns 14,617,205 shares of the company’s stock valued at $780,119,000 after purchasing an additional 9,442,207 shares during the period. Marshall Wace North America L.P. purchased a new position in Zoetis during the 1st quarter valued at about $243,854,000. Alliancebernstein L.P. increased its position in Zoetis by 55.4% during the 2nd quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock valued at $646,905,000 after purchasing an additional 3,695,449 shares during the period. Finally, Waddell Reed Financial Inc. increased its position in Zoetis by 65.9% during the 1st quarter. Waddell Reed Financial Inc. now owns 5,434,371 shares of the company’s stock valued at $290,033,000 after purchasing an additional 2,157,803 shares during the period. 93.20% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This piece was first published by Week Herald and is the property of of Week Herald. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States international copyright and trademark laws. The legal version of this piece can be accessed at https://weekherald.com/2017/09/25/capital-fund-management-s-a-sells-329998-shares-of-zoetis-inc-zts.html.
Shares of Zoetis Inc. (NYSE:ZTS) opened at 64.16 on Monday. Zoetis Inc. has a 52 week low of $46.86 and a 52 week high of $65.83. The firm has a market capitalization of $31.38 billion, a PE ratio of 36.27 and a beta of 1.02. The firm’s 50-day moving average is $62.44 and its 200 day moving average is $59.64.
Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.53. The business had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The business’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.49 EPS. On average, equities analysts forecast that Zoetis Inc. will post $2.34 earnings per share for the current year.
A number of brokerages have recently issued reports on ZTS. BidaskClub raised shares of Zoetis from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 12th. Cowen and Company set a $70.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research report on Monday, July 17th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Zoetis in a research report on Wednesday, September 6th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $65.00 price objective (up previously from $62.00) on shares of Zoetis in a research report on Monday, July 17th. Finally, Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a research report on Tuesday, June 20th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $65.44.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News Ratings for Zoetis Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.